Hikma Pharmaceuticals (LON:HIK) Shares Down 14.1% – Here’s What Happened

Shares of Hikma Pharmaceuticals PLC (LON:HIK) traded down 14.1% during trading on Thursday . The stock traded as low as GBX 1,522 and last traded at GBX 1,522. 166,325,172 shares traded hands during mid-day trading, an increase of 7,989% from the average session volume of 2,056,107 shares. The stock had previously closed at GBX 1,771.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Deutsche Bank Aktiengesellschaft lowered their price objective on shares of Hikma Pharmaceuticals from GBX 3,100 to GBX 2,850 and set a “buy” rating on the stock in a research report on Tuesday, August 12th. Berenberg Bank lowered their price target on shares of Hikma Pharmaceuticals from GBX 2,560 to GBX 2,510 and set a “buy” rating on the stock in a research report on Thursday, October 16th. JPMorgan Chase & Co. lowered their price target on shares of Hikma Pharmaceuticals from GBX 2,600 to GBX 2,500 and set an “overweight” rating on the stock in a research report on Friday, August 8th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a GBX 2,600 price target on shares of Hikma Pharmaceuticals in a research report on Thursday, August 7th. Four analysts have rated the stock with a Buy rating, According to MarketBeat, Hikma Pharmaceuticals has an average rating of “Buy” and an average target price of GBX 2,615.

Hikma Pharmaceuticals Stock Performance

The company has a 50-day moving average price of GBX 1,740.80 and a two-hundred day moving average price of GBX 1,898.69. The company has a current ratio of 1.66, a quick ratio of 1.27 and a debt-to-equity ratio of 55.82. The stock has a market capitalization of £3.37 billion, a P/E ratio of 9.11, a price-to-earnings-growth ratio of 2.38 and a beta of 0.41.

Insider Activity

In related news, insider Mazen Darwazah bought 14,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 16th. The shares were bought at an average price of GBX 1,603 per share, for a total transaction of £224,420. Also, insider Laura Balan Balan purchased 3,500 shares of the company’s stock in a transaction dated Friday, August 22nd. The shares were acquired at an average price of GBX 1,821 per share, for a total transaction of £63,735. Corporate insiders own 17.77% of the company’s stock.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.